VERTEX PHARMACEUTICALS BCG MATRIX TEMPLATE RESEARCH B_105 8B Cybersecurity (2024) Medium Geographic

8B Cybersecurity (2024) Medium Geographic Expansion Various

Market Size: Smaller overall

Dogs in S2 Genomics' BCG matrix include low-performing products with little market share

4% in 2025 to COP 1

with AI integration expected to boost growth by 20% annually

VERTEX PHARMACEUTICALS BCG MATRIX TEMPLATE RESEARCH B_105 8B Cybersecurity (2024) Medium GeographicDownload Your Competitive Advantage Vertex Pharmaceuticals sits at the intersection of high growth innovation and concentrated product risk its breakthrough CF therapies are clear Stars with strong market share and cash generation potential, while earlier stage gene editing programs read as Question Marks that could flip the portfolio's future value; a few aging or niche assets behave like Dogs in need of divestiture. Dive deeper into this company's